Design of silicon-based misonidazole analogues and 18F-radiolabelling

Nuclear Medicine and Biology

Volumn 36, Issue 8, 2009, Pages 895-905

  Bohn, Pierre ^a   Deyine, Abdallah ^a,b   Azzouz, Rabah ^b   Bailly, Laetitia ^b   Fiol Petit, Catherine ^b   Bischoff, Laurent ^b   Fruit, Corinne ^b   Marsais, Francis ^b   Vera, Pierre ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b INSA   (France)

Author keywords

Fluorine 18; fluorosilane; hypoxia; misonidazole; PET imaging; radiolabelling

Indexed keywords

1 [3 (ETHOXYDINAPHT 1 YLSILYL)PROPYL] 2 NITRO 1H IMIDAZOLE F 18; 1 [3 (ETHOXYDIPHENYLSILYL)PROPYL] 2 NITRO 1H IMIDAZOLE F 18; 1 [3 (FLUORODIISOPROPYLSILYL)PROPYL] 2 NITRO 1H IMIDAZOLE F 18; 1 [3 (FLUORODINAPHT 1 YLSILYL)PROPYL] 2 NITRO 1H IMIDAZOLE F 18; 1 [3 (ISOPROPYLOXYDIISOPROPYLSILYL)PROPYL] 2 NITRO 1H IMIDAZOLE F 18; 1 [3 (ISOPROPYLOXYDIMETHYLSILYL)PROPYL] 2 NITRO 1H IMIDAZOLE F 18; 1 [3 (TERT BUTYLOXYDIMETHYLSILYL)PROPYL]QUINUCLIDINIUM CHLORIDE F 18; 2 NITROIMIDAZOLE; CHLORO (3 CHLOROPROPYL)DIISOPROPYLSILANE F 18; CHLORO (3 CHLOROPROPYL)DINAPHT 1 YLSILANE F 18; CHLORO (3 CHLOROPROPYL)DIPHENYLSILANE F 18; ETHOXY (3 CHLOROPROPYL)DINAPHT 1 YLSILANE F 18; ETHOXY (3 CHLOROPROPYL)DIPHENYLSILANE F 18; ISOPROPYLOXY (3 CHLOROPROPYL)DIISOPROPYLSILANE F 18; ISOPROPYLOXY (3 CHLOROPROPYL)DIMETHYLSILANE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DEFLUORINATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; HYPOXIA; IN VIVO STUDY; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SOLID TUMOR; STEREOSPECIFICITY; STRUCTURE ANALYSIS;

ANIMALS; CELL LINE, TUMOR; FIBROSARCOMA; FLUORINE RADIOISOTOPES; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C3H; MISONIDAZOLE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; SILICON; TISSUE DISTRIBUTION;

EID: 70350404654     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.06.004     Document Type: Article

References (44)

1. Ametamey S.M., Honer M., and Schubiger P.A. Molecular imaging with PET. Chem Rev 108 (2008) 1501-1516
2. Miller P., Long N.J., Vilar R., and Gee A. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed 47 (2008) 8998-9033
3. Cai L., Innis R.B., and Pike V.W. Radioligand development for PET imaging of β-amyloid (Aβ)-current status. Curr Med Chem 4 (2007) 19-52
4. Cohen R.M. The application of positron-emitting molecular imaging tracers in Alzheimer's disease. Mol Imaging Biol 9 (2007) 204-216
5. Mercer J.R. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential. J Pharm Sci 10 (2007) 179-200
6. Wiebe L.I. PET radiopharmaceuticals for metabolic imaging in oncology. International Congress Series 1264 (2004) 53-76
7. 18F]Fluoride ion. Eur J Org Chem 17 (2008) 2853-2873
8. Purser S., Moore P.R., Swallow S., and Gouverneur V. Fluorine in medicinal chemistry. Chem Soc Rev 37 (2008) 320-330
9. 18F-radiochemistry: syntheses and applications. Mini-Rev Org Chem 4 (2007) 317-329
10. Dolle F, Perrio C, Barre L, Lasne M-C, Le Bars, D. Fluorine-18-labeled molecules: synthesis and application in medical imaging. Actualite Chimique (Publisher: Societe Francaise de Chimie) 2006;301-302:93-98.
11. +-emitting compounds based on fluorine-18. Topics in current chemistry 222 (2002), Springer-Verlag, Berlin-Heidelberg 201-258
12. 18F]Fluoro-d-Glucose (18FDG). In: Welch M.J., and Redvanly C.S. (Eds). Handbook of radiopharmaceuticals, radiochemistry and applications (2003), Wiley, Chichester
13. 18F]2-Fluoro-2-deoxy-d-glucose. Angew Chem Int Ed 46 (2007) 941-944
14. Grierson J.R., Link J.M., Mathis C.A., Rasey J.S., and Krohn K.A. A radiosynthesis of fluorine-18Fluoromisonidazole. J Nucl Med 30 (1989) 343-350
15. 18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues. Appl Radiat Isot 40 (1989) 117-126
16. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nuclear Medicine and Biology 30 (2003) 317-326
17. 18F]-N-fluorobenzenesulfonimide. Chem Commun (2007) 2330-2332
18. Boldon S., Moore J.E., and Gouverneur V. Fluorous synthesis of allylic fluorides: C-F bond formation as the detagging process. Chem Commun (2008) 3622-3624
19. Walsh J.C., Akhoon K.M., Stayamurthy N., Barrio J.R., Phelps M.E., Gambhir S.S., and Toyokuni T.J. Labelled Compd Radio-pharm 42 (1999) S1-S3
20. 18F]fluorotrimethylsilane. Int J Appl Radiat Isot 36 (1985) 318-319
21. Schirrmacher R., Bradtmöller G., Schirrmacher E., Thews O., Tillmanns J., Siessmer T., et al. 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed 45 (2006) 6047-6050
22. 18F-labeling of N-amino-oxy derivatized peptides. Bioconjugate Chem 18 (2007) 2085-2089
23. 18F]FA-SH) labeled rat serum albumin for blood pool imaging with PET. Bioconjugate Chem 20 (2009) 317-321
24. 18F-radiolabeling of peptides for PET imaging. Angew Chem Int Ed 47 (2008) 4922-4925
25. 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjugate Chem 19 (2008) 1871-1879
26. Srinivasan A., Lehmann L., Voigtmann U., Stellfels T., Ametamey S.M., Klar U., et al. Preparation of silicon compounds labeled with fluorine-18 for PET imaging. PCT Int Appl (2008) WO 2008040441, 155 p
27. Höhne A., Yu L., Mu L., Reiher M., Voigtmann U., Klar U., et al. Organofluorosilanes as model compounds for 18F-labeled silicon-based PET tracers and their hydrolytic stability: experimental data and theoretical calculations (PET=positron emission tomography). Chemistry A Eur J 15 (2009) 3736-3743
28. 18F-labeling J. Am Chem Soc 127 (2005) 13094-13095
29. 18F]Fluorodeoxyglucose positron emission tomography imaging. Clinical Cancer Res 10 (2004) 2245-2252
30. 18F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiotherapy and Oncology 83 (2007) 406-410
31. Cook G.J.R., and Fogelman I. Tumor hypoxia: the role of nuclear medicine. Eur J Nucl Med 25 (1998) 335-337
32. Bache M., Kappler M., Said H.M., Staab A., and Vordermark D. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 15 (2008) 322-338
33. Brizel D.M., Scully S.P., Harrelson J.M., Layfield J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
34. Bristow R.G., and Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Rev Cancer 8 (2008) 180-192
35. Tang G., Wang M., Tang X., Gan M., and Luo L. Fully automated one-pot synthesis of [18F]fluoromisonidazole. Nuclear Medicine and Biology 32 (2005) 553-558
36. Kämäräinen E.L., Kyllönen T., Nihtilä O., Björk H., and Solin O. Preparation of fluorine-18-labeled fluoromisonidazole using two different synthesis methods. J Label Compd Radiopharm 47 (2004) 37-45
37. Surti S., Karp J.S., Perkins A.E., Cardi C.A., Daube-Witherspoon M.E., Kuhn A., et al. Imaging performance of A-PET: a small animal PET camera. IEEE Transactions on Medical Imaging 24 (2005) 844-852
38. Milas L., Hunter N., Mason K., and Withers H.R. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res 34 (1974) 61-71
39. Masaoka S., Banno T., and Masaoka M. Versatile method for introduction of bulky substituents to alkoxychlorosilanes. J Organometallic Chem 691 (2006) 182-192
40. Weinmann M., Gehrig A., Schiemenz B., Huttner G., Nuber B., and Rheinwald G. Penta-coordinated chlorosilanes: reaction chemistry, structure and bonding. J Organometallic Chem 563 (1998) 61-72
41. Cho H.M., Jang J.I., Kim C.H., Lee S.G., and Lee M.E. Syntheses and NMR study of[(2-dimethylaminomethyl)phenyl]vinylsilane derivatives and[(2-dimethylaminomethyl)-phenyl]ethylsilane derivatives. J Organometallic Chem 679 (2003) 43-47
42. Addition of anti-oxidant stabilizers such as Ascorbic acid or ethanol into radiochemical solution was also considered: Scott PJH, Hockley BG, Kung HF, Manchanda R, Zhang W, Kilbourn MR. Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography. Applied Radiation and Isotopes 2008;67:88-94.
43. cLog P were calculated with ChemDraw Ultra for Mac v 11.0.1
44. Choudhry U., Paul R., Blower P., and Biagini S. Rapid reaction of alkoxysilanes with [F-18]-fluoride as a basis for biomolecule labelling for PET. Eur J Nucl Med Mol Imaging 34 (2007) S332